Written by Levan Darjania Ph.D.
CBD Reality Check
Interest in the therapeutic use of hemp-derived nonintoxicating cannabinoids such as cannabidiol (CBD) and cannabigerol (CBG) has reached a fever pitch in recent years followed by the early-stage preclinical discoveries surrounding the tentative functional role of the endocannabinoid system (ECS). CBD received a further popular validation since U.S. FDA approved Epidiolex® as adjunctive therapy for pediatric patients with drug-resistant epilepsy.
During the last 5-8 years, CBD has been highly acclaimed and heavily hyped. Its medicinal qualities are perceived as limitless by some, and its non-psychoactive nature makes it “suitable” for just about anyone, as it has been claimed by many activists and business entities. The broad-ranging claims of CBD therapeutic utilities are endless, while monopolistic entrepreneurs are rushing the industry in droves, touting first to market achievements over quality, research-backed product offerings.
Current Status-Quo and Future Expectations
The majority of CBD companies purportedly ignore the lack of efficacy in their products in an attempt to rationalize the commercial utility of CBD and exploit the “natural” label without any R&D efforts to characterize their marketed products concerning their wellness-associated benefits, which could establish a certain level of evidence-based credibility for mentioned marketed products. Companies marketing products containing CBD have been over-exuberant in their claims about its effectiveness. They have been guilty of illegal, sleight-of-hand, exploiting public enthusiasm over cannabis/hemp by portraying all cannabinoids as not only safe but capable of ameliorating the symptoms of many serious medical conditions.
Consequently, the reputation of CBD as a universal “cure-all” puts this still promising substance in the same class as other “natural” panaceas, where anecdotal cases and overwhelmingly biased testimonials supersede the proper efficacy evaluation of already marketed CBD finished products.
Notwithstanding, while CBD and other hemp-derived cannabinoids remain a formally unproven therapeutic option with a known mechanism of action, physicians and holistic health/wellness practitioners remain open to the possible future role of these products in the field of alternative management and prophylaxis of different health conditions such as chronic inflammation and pain.
Emerging companies like Green Hygienics Holdings Inc. (OTCQB: GRYN) have an opportunity to paint a brighter future for the CBD industry and provide a research-based platform for which these physicians and holistic health/wellness practitioners can specifically select and recommend beneficial products meaningful to their intended purpose of providing patient relief.
To recommend a particular cannabinoid-based product to patients and wellness-oriented end-users, those practitioners need to adequately analyze specific information and study reports on the experimentally assessed systemic exposure, bioavailability, and targeted efficacy of a particular product, instead of focusing solely on the certificate of analysis (COA) that verifies only the concentration of bio-active ingredients and absence of harmful contaminants.
A very brief survey gathered from the published scientific and commercial papers or conference presentations indicates that even the major players in the CBD market do not possess such study results and reports to differentiate and promote their products based on at least preclinical and/or exploratory clinical study findings.
Green Hygienics (“GRYN”) is Poised to Address the Current State of the Industry
On the other hand, this particular status-quo represents the immense opportunities for R&D-driven companies like Green hygienics in an everchanging cannabinoid market landscape. Physicians and holistic health/wellness practitioners are looking for more advanced, evidence-based cannabinoid products with high, unparalleled, and most importantly unbiased therapeutic efficacies of achievable health-beneficial effects. Green Hygienics is an enterprise that has developed a model resting on this exact premise of bringing evidence-based cannabinoid products to market, backed with unbiased therapeutic efficacies, through research-based evidence.
The company aims to be a leader in compliance and capabilities in the hemp and cannabinoid supply marketplace. By leveraging state-of-the-art technologies, the company intends to open up a whole new world of fully characterized novel cannabinoids and targeted bio-delivery technologies never before explored.
Green Hygienics is aimed at maximizing the use of intellectual and capital resources. Therefore, the Company has decided to move forward with the establishment of a state-of-art biotechnology R&D facility to focus its resources on the rational and innovative design of formulations, development, and experimental evaluation of the new generation cannabinoid-based products with superior bioavailability and specifically assessed health-wellness efficacies.
Discovery and development of highly efficacious cannabinoid-based products is a global task that is based on multidisciplinary approaches, collaborations, and partnerships. Therefore, Green Hygienics is building its collaborative platform with several academic institutions both domestically and abroad to utilize well-established endocannabinoid system (ECS) target screening models and develop customized wellness products addressing ECS deficiencies. The ultimate goal is to develop and promote highly functional, experimentally assessed, and supported efficacious nutraceutical products that will be trusted by medical communities, physicians, holistic health practitioners, and wellness-oriented end users.
About Green Hygienics Holdings
Green Hygienic Holdings Inc. (OTCQB: GRYN) (“Green Hygienics” or the “Company”) is a California-based innovative, technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids.
The Company’s corporate mission is to adhere to the highest standards of operations in consistently delivering safe and premium-quality products to consumers as well as to partner with CPG (consumer packaged goods) and pharmaceutical companies.
The Company intends to be a leader in compliances and capabilities in the hemp and cannabinoid supply marketplace. Using state-of-the-art technologies, Green Hygienics intends to open a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration, and bioavailability.
We are building a team of visionary agrotechnology, pharmaceutical, and life scientists working at the intersection of nutraceutical, cosmeceutical, and pharmaceutical technologies with a goal to improve lives.
For further information about Green Hygienics Holdings Inc., please visit the Company’s website at:
Corporate Communications: Heidi Thomasen Thomasen Communications IR@GreenHygienics.com Toll-Free 1.855.802.0299
This content is provided as a membership benefit to our valuable business level members. Due to several factors including the variances in state hemp laws and the differences in interpretation of federal law, NHA makes no warrants of the legality, efficacy or safety of any product, service or statement made by any third party.
We encourage all members and the general public to do their own due diligence on any business or product, and understanding their state’s and federal laws, before choosing to purchase any product or contracting for any service